Anna Ter-Zakarian
Hematology & Oncology · South Pasadena, CANPI 1174085492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,094 and has fallen 65.0% since, to $383 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 69 payments — averaging $35.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$534
- Incyte Corporation$234
- AstraZeneca$225
- AbbVie$194
- Eisai Inc.$179
- Gilead$125
- plus $954 from 24 others
What the payments were for
- Food & beverage$2,27393%
- Education$1727%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $534 |
| Incyte Corporation | 5 | $234 |
| AstraZeneca(2 entities) | 5 | $225 |
| AbbVie | 4 | $194 |
| Eisai Inc. | 8 | $179 |
| Gilead | 1 | $125 |
| Pharmaessentia USA Corporation | 3 | $101 |
| Blueprint Medicines Corporation | 3 | $81 |
| Johnson & Johnson | 3 | $70 |
| Novartis | 2 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $60 |
| Seagen Inc. | 2 | $60 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Stemline Therapeutics Inc. | 2 | $55 |
| Pfizer | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| GSK | 1 | $30 |
| AVEO Pharmaceuticals, Inc. | 1 | $30 |
| ADC Therapeutics America, Inc. | 1 | $29 |
| Array Biopharma Inc | 1 | $27 |
| Boehringer Ingelheim | 1 | $27 |
| Beigene USA, Inc. | 1 | $25 |
| Bayer | 1 | $24 |
| Genmab U.S., Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Merck | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| CSL Behring | 1 | $17 |
| Sobi, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,445 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 15 | $166 |
| Prednisone | 12 | $86 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in South Pasadena
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.